Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — 42nd Annual J.P. Morgan Healthcare Conference 2024
14 slides from Abcellera Biologics's conference presentation, Jan 10, 2024
Slide 1: Corporate Overview
CORPORATE OVERVIEW COPYRIGHT © ABCELLERA JPM Healthcare Conference 2024
Slide 2: Disclaimer
DISCLAIMER This presentation contains forward-looking statements, including These statements involve risks, uncertainties and other factors that may JPM HEALTHCARE CONFERENCE 2024 statements made pursuant to the safe harbor provisions of the Private cause actual results, levels of activity, performa
Slide 3: The most important drivers of productivity in drug development
The most important drivers of productivity in drug development are: JPM HEALTHCARE CONFERENCE 2024 New insights into Novel solutions to the biology of disease challenging problems COPYRIGHT © ABCELLERA 3
Slide 4: We have built an engine to generate first-in-class and best-in-class antibody medicines
We have built an engine to generate first-in-class and best-in-class antibody medicines. JPM HEALTHCARE CONFERENCE 2024 Build a competitive advantage Investments in technological capability can improve the productivity of drug development. So you can solve hard problems Long-term value creation come
Slide 5: Overview
OVERVIEW AbCellera’s engine is Capitalization Portfolio of Partnered Programs broadly applicable within $1B+* in liquidity 110 discovery program * partner-initiated the $400B1 antibody $200M+ from non- JPM HEALTHCARE CONFERENCE 2024 dilutive government starts** funding 10 the clinic * $800M+ in tota
Slide 6: Our Partners
OUR PARTNERS We are increasingly Expanding relationships focused on strategic with large pharma and large biotech JPM HEALTHCARE CONFERENCE 2024 partnerships. T-cell engager platform We look for partnerships that bring new insights into novel biology deals in oncology and autoimmune or access to uni
Slide 7: Our Pipeline
OUR PIPELINE Advancing an internal pipeline First two IND submissions anticipated in 2025. of potential first-in-class and We intend to take additional first-in-class development candidates into IND-enabling best-in-class assets is a top studies in 2024 and 2025. JPM HEALTHCARE CONFERENCE 2024 prior
Slide 8: Our Pipeline - ABCL575
OUR PIPELINE - ABCL575 Molecule ABCL575 Status IND-enabling studies (Preclinical) ABCL575 is Target OX40 ligand (OX40L) JPM HEALTHCARE CONFERENCE 2024 MOA Blocking and non-depleting a potential Indication • Atopic dermatitis (AD) best-in-class and • Other indications in autoimmunity and inflammation
Slide 9: Our Pipeline – ABCL635
OUR PIPELINE – ABCL635 Molecule ABCL635 Status IND-enabling studies (Preclinical) A potential Target Undisclosed - GPCR or ion channel JPM HEALTHCARE CONFERENCE 2024 MOA Antagonist first-in-class Indication Undisclosed antibody therapy Therapeutic Area Metabolic & endocrine conditions for metabolic
Slide 10: Our Engine: T-Cell Engager Platform
OUR ENGINE: T-CELL ENGAGER PLATFORM Continued progress and differentiation for T-cell engager platform. T-cell engagers have tremendous potential for the treatment of cancer and autoimmune conditions but are technically challenging to design and engineer. JPM HEALTHCARE CONFERENCE 2024 AbCellera’s T
Slide 11: Our Engine: T-Cell Engager Platform – Reducing dose-limiting toxicity
OUR ENGINE: T-CELL ENGAGER PLATFORM Reducing dose-limiting toxicity associated with cytokine release. Selection of CD3 binders that achieve potent cell killing with very low cytokine release on an undisclosed target. JPM HEALTHCARE CONFERENCE 2024 Example molecule Potent tumor-cell killing Low cytok
Slide 12: Our Engine: T-Cell Engager Platform – Expanding the target space
OUR ENGINE: T-CELL ENGAGER PLATFORM Expanding the target space: Discovery platform enables generation of diverse and highly specific pMHC binders. JPM HEALTHCARE CONFERENCE 2024 Example molecules 1 1 2 3 Tumor-cell 100 killing (%) MAGE-A4+ cells 50 AbCellera molecules 0 Molecule R 400 TNFα MAGE-A4 k
Slide 13: Summary
SUMMARY Completion of Engine Continued focus Over the next 2 years we will continue to invest in the final stage of our engine, including construction and on high-value commissioning of our manufacturing facility. JPM HEALTHCARE CONFERENCE 2024 Our Portfolio of Partnered Programs programs In 2024, w
Slide 14: Thank You
COPYRIGHT © ABCELLERA 14 JPM HEALTHCARE CONFERENCE 2024 YOU THANK
AbCellera Biologics — 42nd Annual J.P. Morgan Healthcare Conference 2024 on 6ix